{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:45:59Z","timestamp":1791931559957,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National High Level Hospital Clinical Research Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T-cell) therapy is an established treatment for relapsed\/refractory multiple myeloma. However, its application in POEMS syndrome remains largely unreported, despite overlapping pathogenesis involving plasma cell dyscrasia. Herein, we present a woman in her 30s with heavily pretreated relapsed\/refractory POEMS syndrome who received equecabtagene autoleucel, a fully human anti-BCMA CAR T-cell product. The patient achieved a complete vascular endothelial growth factor (VEGF) response by day 14 post-infusion, with sustained remission through 12 months of follow-up. Clinical improvements included resolution of heart failure, pulmonary hypertension, and renal dysfunction, along with marked neurological recovery, enabling the patient to return to normal daily activities and occupational functioning, a status that persisted through the 16-month follow-up. Treatment-related toxicities comprised Grade 2 cytokine release syndrome and persistent hypogammaglobulinemia, without severe infectious complications. No delayed neurotoxicity or secondary malignancies were observed. This case provides evidence that BCMA CAR T-cell therapy is a safe and efficacious option for patients with relapsed\/refractory POEMS syndrome.<\/jats:p>","DOI":"10.1007\/s00277-026-07224-5","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:51:42Z","timestamp":1786157502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed\/refractory POEMS Syndrome: a case report"],"prefix":"10.1007","volume":"105","author":[{"given":"Hongxiao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaini","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"8","key":"7224_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"21","key":"7224_CR2","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, Jiang L, Meng L, Yang Y, Zhou X, Hong Z, Yao Z, Xiao M, Chen L, Mao X, Zhu L, Wang J, Qiu L, Li C, Zhou J (2021) A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137(21):2890\u20132901. https:\/\/doi.org\/10.1182\/blood.2020008936","journal-title":"Blood"},{"issue":"6","key":"7224_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/jco.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O\u2019Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S (2023) Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol 41(6):1265\u20131274. https:\/\/doi.org\/10.1200\/jco.22.00842","journal-title":"J Clin Oncol"},{"issue":"12","key":"7224_CR4","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/ajh.27081","volume":"98","author":"A Dispenzieri","year":"2023","unstructured":"Dispenzieri A (2023) POEMS syndrome: Update on diagnosis, risk-stratification, and management. Am J Hematol 98(12):1934\u20131950. https:\/\/doi.org\/10.1002\/ajh.27081","journal-title":"Am J Hematol"},{"issue":"3","key":"7224_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00277-018-03589-4","volume":"98","author":"T He","year":"2019","unstructured":"He T, Zhao A, Zhao H, Cai H, Feng J, Zhang L, Cao X, Zhou D, Li J (2019) Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy. Ann Hematol 98(3):735\u2013743. https:\/\/doi.org\/10.1007\/s00277-018-03589-4","journal-title":"Ann Hematol"},{"issue":"4","key":"7224_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"7224_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, J\u00e4ger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, S\u00e1nchez-Guijo F, S\u00e1nchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I (2023) Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142(10):865\u2013877. https:\/\/doi.org\/10.1182\/blood.2023020578","journal-title":"Blood"},{"issue":"4","key":"7224_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41375-019-0391-2","volume":"33","author":"H Zhao","year":"2019","unstructured":"Zhao H, Huang XF, Gao XM, Cai H, Zhang L, Feng J, Cao XX, Zhou DB, Li J (2019) What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia 33(4):1023\u20131029. https:\/\/doi.org\/10.1038\/s41375-019-0391-2","journal-title":"Leukemia"},{"issue":"12","key":"7224_CR9","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","volume":"10","author":"C Li","year":"2024","unstructured":"Li C, Zhou K, Hu Y, Zou D, Chen L, Chen B, Liu J, Zhang X, Ren H, Hu K, Liu P, Mi JQ, Li Z, Ding K, Wang D, Wang W, Cai S, Li J, Song Y, Huang H, Qiu L (2024) Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial. JAMA Oncol 10(12):1681\u20131688. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4879","journal-title":"JAMA Oncol"},{"issue":"1","key":"7224_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","volume":"11","author":"J Xu","year":"2018","unstructured":"Xu J, Wang Q, Xu H, Gu C, Jiang L, Wang J, Wang D, Xu B, Mao X, Wang J, Wang Z, Xiao Y, Zhang Y, Li C, Zhou J (2018) Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol 11(1):128. https:\/\/doi.org\/10.1186\/s13045-018-0672-7","journal-title":"J Hematol Oncol"},{"issue":"11","key":"7224_CR11","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3324\/haematol.2025.287702","volume":"110","author":"M Williams","year":"2025","unstructured":"Williams M, Atanackovic D, Mulatu R, Matsangos A, Yamoah D, Badros A (2025) Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study. Haematologica 110(11):2859\u20132863. https:\/\/doi.org\/10.3324\/haematol.2025.287702","journal-title":"Haematologica"},{"issue":"5","key":"7224_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood.2024027681","volume":"146","author":"SA Tuazon","year":"2025","unstructured":"Tuazon SA, Portuguese AJ, Pont MJ, Cowan AJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu QV, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Riddell SR, Green DJ (2025) A phase 1 trial of fully human BCMA CAR-T therapy for relapsed\/refractory multiple myeloma with 5-year follow-up. Blood 146(5):535\u2013545. https:\/\/doi.org\/10.1182\/blood.2024027681","journal-title":"Blood"},{"issue":"23","key":"7224_CR13","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","volume":"5","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li C, Xia J, Li P, Cao J, Pan B, Tan X, Li H, Qi K, Wang X, Shi M, Jing G, Yan Z, Cheng H, Zhu F, Sun H, Sang W, Li D, Zhang X, Li Z, Zheng J, Liang A, Zhou J, Xu K (2021) Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Adv 5(23):5290\u20135299. https:\/\/doi.org\/10.1182\/bloodadvances.2021004603","journal-title":"Blood Adv"},{"issue":"7","key":"7224_CR14","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"SK Thiruvengadam","year":"2022","unstructured":"Thiruvengadam SK, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, Natsuhara K, Martin T, Wolf J, Shah N, Wong SW (2022) Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv 6(7):2045\u20132054. https:\/\/doi.org\/10.1182\/bloodadvances.2020004079","journal-title":"Blood Adv"},{"key":"7224_CR15","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","volume":"38","author":"JA Hill","year":"2019","unstructured":"Hill JA, Giralt S, Torgerson TR, Lazarus HM (2019) CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev 38:100596. https:\/\/doi.org\/10.1016\/j.blre.2019.100596","journal-title":"Blood Rev"},{"issue":"6","key":"7224_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20(6):359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07224-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:03:00Z","timestamp":1791928980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07224-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7224"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07224-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital and was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the participant.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests that are directly or indirectly related to the work submitted for publication.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"456"}}